SGRY at a glance
Surgery Partners, Inc. (SGRY, SEC CIK 1638833) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as August 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Surgery Partners, Inc. (SGRY) reported revenue of $3.3 billion (up 6.2% from FY2024) and a net loss of $77.9 million. Diluted EPS was -$0.61.
- As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Surgery Partners, Inc. (SGRY) shares worth $382.0 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by DeLuca Teresa on August 18, 2026 of 10,000 shares at $14.35 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.3B
- +6.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $382.0M · −3 vs prior quarter
- Latest 8-K
- Nov 18, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Management and operation of surgical facilities primarily focused on outpatient surgical procedures
- New emphasis: Increased revenue diversification from management and administrative services in non-owned surgical facilities
- Strategic shift: Improved operational efficiency reflected in decreased general and administrative expenses ratio, from 4.5% in 2024 to 3.6% in 2025
- Quantitative metric: Revenue growth to $3.31 billion in 2025, up 6.3% from $3.11 billion in 2024, driven by 3.4% volume and 1.4% revenue per case increases
- Noteworthy fact: Significant increase in interest expense to $272.6 million (8.2% of revenues) due to maturity of interest rate swaps and new unsecured notes
Risk Factors
- Regulatory risk from One Big Beautiful Bill Act (OBBBA), effective July 4, 2025, increasing Medicaid and Medicare regulatory burdens
- Macroeconomic exposure to government payors, comprising 42.8% of patient service revenues in 2025
- Operational risk tied to partnership model with physicians owning majority in 86 of 176 surgical facilities
- Competitive threat from decline in ophthalmology cases, dropping from 24.4% to 21.7% of surgical mix 2023-2025
- Financial leverage risk with $692.8 million borrowing capacity under Revolver and $239.9 million cash holdings as of 12/31/2025
Management Discussion & Analysis
- Adjusted EBITDA $526.2M in 2025 vs $508.2M in 2024, income before taxes $116.9M vs $147.1M in 2024
- Operating cash flow $274.3M in 2025, Credit Agreement EBITDA $578.2M reflecting acquisitions and synergies
- Refinanced $1.4B term loans with interest rate ~6.22%, issued $425M senior unsecured notes due 2032 at 101%
- Net working capital $535.2M at Dec 31, 2025 vs $495.0M in 2024, total debt obligations $5.7B including interest
- Management highlights economic risks: interest rate inflation could pressure payor mix, patient volume and liquidity; expects capital markets access to meet liquidity needs
AI summary of the SGRY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $815.3M, down 0.8% YoY from $821.5M, despite same-facility revenue growth of 6.0%
- Cost margin 77.3% vs 76.2% YoY, operating margin 10.5% vs 12.9%, net loss $21.1M vs $22.7M
- Best performance: same-facility revenue per case up 5.8%; worst: other service revenue $17.3M vs $23.0M
- Cash $354.5M vs $239.9M at December 31, 2025; operating cash flow $174.5M, up from $170.9M
- $285.0M Term Loan prepayment; outlook supported by operating cash flow, cash and $692.8M Revolver capacity, with inflation and supply-chain risks remaining headwinds
Risk Factors
- Merger completion risk, triggered by October 23 agreement and November 8 amendment, with HSR clearance and stockholder approval required
- Termination exposure: approximately $149.1 million fee plus expense reimbursement capped at $8.25 million
- Regulatory risk: Hart-Scott-Rodino waiting-period termination or injunction could prevent closing
- Operational risk: merger uncertainty may cause key personnel departures and impair execution
- Litigation risk: securities or derivative lawsuits could delay closing and reduce liquidity
AI summary of the SGRY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Consent fee doubled to $5.00 per $1,000 from $2.50 for timely, non-revoked consents
- Applies to $1,225,000,000 of 7.250% senior notes due 2032
Item 7.01: Regulation FD Disclosure
- Consent fee doubled to $5.00 per $1,000 of notes, from $2.50, increasing the issuer’s cost to secure approval
- Solicitation covers $1.225B of 7.250% senior notes due 2032, creating a potentially material transaction expense
Item 7.01: Regulation FD Disclosure
- Consent solicitation for $1.225B of 7.250% Senior Notes due 2032 tied to proposed BSMH acquisition
- Proposed amendments would designate BSMH, HealthSpan Partners and affiliates as permitted holders under the indenture
Item EX-99.1: Item EX-99.1
- Consent solicitation on $1.225B of 7.250% senior notes due 2032 to facilitate the proposed BSMH-backed merger
- Without amendments, merger triggers a change-of-control offer at 101% of principal plus accrued interest
Item 1.01: Entry into a Material Definitive Agreement
- Merger consideration raised to $25.00 per share in cash, improving shareholder economics
- 10% annual ticking fee after March 1, 2027 if approval is obtained but closing is delayed, capped at $1.61 per share
Item 7.01: Regulation FD Disclosure
- Press release announces entry into an Amendment, making the revised agreement the key investor focus
- Exhibit 99.1 contains the amendment announcement and likely substantive terms
Item EX-99.1: Item EX-99.1
- Amended HealthSpan merger raises consideration to $25 per share, valuing Surgery Partners at up to approximately $6.0 billion enterprise value
- Ticking Fee adds up to $1.61 per share if approval occurs before March 1, 2027 but closing extends to October 23, 2027
AI summaries of SGRY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SGRY
Don't miss the next SGRY filing
- Alerts as it files. A push when SGRY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SGRY, by share count.
- Ask anything. An AI agent that reads every SGRY filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| DeLuca Teresa | Buy | Aug 18, 2026 | 10,000 | $14.35 |
| DeLuca Teresa | Buy | Aug 18, 2026 | 11,250 | $14.33 |
| HENDRIX BLAIR E | A | Jun 18, 2026 | 34,364 | $14.55 |
| Forese Laura L | A | Jun 5, 2026 | 11,670 | $13.71 |
| Deane John A | A | Jun 5, 2026 | 11,670 | $13.71 |
| DeLuca Teresa | A | Jun 5, 2026 | 11,670 | $13.71 |
| TURNER BRENT | A | Jun 5, 2026 | 11,670 | $13.71 |
| ADLERZ CLIFFORD G | A | Jun 5, 2026 | 11,670 | $13.71 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $3.1B | $3.3B |
| Operating Income | - | $348.8M | $389.5M |
| Net Income | -$11.9M | -$168.1M | -$77.9M |
| Op. Margin | - | 11.2% | 11.8% |
| Net Margin | - | -5.4% | -2.4% |
| Balance Sheet | |||
| Total Assets | $6.9B | $7.9B | $8.1B |
| Equity | - | $1.8B | $1.7B |
| ROE | - | -9.4% | -4.5% |
| Per Share | |||
| EPS | $-0.09 | $-1.33 | $-0.61 |
| Cash Flow | |||
| Operating CF | - | $300.1M | $274.3M |
| CapEx | $88.8M | $90.4M | $78.7M |
Source: XBRL data in Surgery Partners, Inc. (SGRY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SGRY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 23 | $382.0M |
| Q2 2026 | 26 | $497.3M |
| Q1 2026 | 27 | $348.2M |
| Q4 2025 | 22 | $518.4M |
| Q3 2025 | 26 | $843.2M |
| Q2 2025 | 26 | $802.1M |
| Q1 2025 | 23 | $679.1M |
| Q4 2024 | 20 | $710.1M |
- Dimensional Fund Advisors+969.8K (+20%)
- BlackRock+405.0K (+6%)
- AQR Capital Management+336.9K (+730%)
- Citadel Advisors LLC+259.1K (+89%)
- State Street Corp+108.7K (+5%)
- Raymond James Financial−804.1K (-93%)
- Goldman Sachs Group−451.2K (-42%)
- Bank of America Corp−239.5K (-20%)
- JPMorgan Chase & Co−228.0K (-71%)
- Morgan Stanley−96.7K (-8%)
- FMR LLC (Fidelity)−2.15M
- Renaissance Technologies LLC−130.1K
- Blackstone Group−15.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 193 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SGRY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Oct 26, 2026 | - | Analysis | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Jul 24, 2026 | - | Analysis | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Mar 16, 2026 | - | - | - |
Related Health Care companies
- ARDT · Ardent Health, Inc.Services-General Medical & Surgical Hospitals, NEC
- CYH · COMMUNITY HEALTH SYSTEMS INCServices-General Medical & Surgical Hospitals, NEC
- HCA · HCA HealthcareServices-General Medical & Surgical Hospitals, NEC
- UHS · Universal Health ServicesServices-General Medical & Surgical Hospitals, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
SGRY SEC filings: frequently asked questions
Which institutions hold SGRY stock?
As of September 30, 2026, the largest Surgery Partners, Inc. (SGRY) holders among the 13F filers tracked by SignalX were BlackRock ($92.2 million), Dimensional Fund Advisors ($82.0 million), Vanguard Portfolio Management LLC ($51.7 million), Vanguard Capital Management LLC ($48.6 million), State Street Corp ($31.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SGRY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Surgery Partners, Inc. (SGRY) reported revenue of $3.3 billion (up 6.2% from FY2024) and a net loss of $77.9 million. Diluted EPS was -$0.61. The figures come from the XBRL data in the 10-K.
What are the main risks in SGRY's latest 10-K?
In the 10-K filed March 2, 2026, Surgery Partners, Inc. (SGRY) flagged: Regulatory risk from One Big Beautiful Bill Act (OBBBA), effective July 4, 2025, increasing Medicaid and Medicare regulatory burdens. Macroeconomic exposure to government payors, comprising 42.8% of patient service revenues in 2025. (AI summary of the Risk Factors section.)
What did SGRY report in its latest 8-K?
Surgery Partners, Inc. (SGRY) filed an 8-K on November 18, 2026 reporting Item 7.01 (Regulation FD Disclosure). Consent fee doubled to $5.00 per $1,000 from $2.50 for timely, non-revoked consents.
What are the latest SGRY SEC filings?
Surgery Partners, Inc. (SGRY) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on August 20, 2026.
What is SGRY's SEC CIK number?
Surgery Partners, Inc. (SGRY)'s SEC Central Index Key (CIK) is 1638833. EDGAR lists every SGRY filing under that number.
Ask anything about SGRY
The research agent reads SGRY's filings, financials, insider trades and 13F holders, then answers with sources.